Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

A Prospective, Multicenter Study Assessing Functional and Psychosocial Parameters in AML Patients ≥ 60 Years Receiving Induction Chemotherapy

Sophie-Luise Mersiowsky, Gabriele Ihorst, Valerie Arnold, Michael J. Müller, Olga Grishina, Claudia Schmoor, Hartmut Bertz, Barbara Deschler-Baier, Ulrich Germing, Björn Hackanson, Michael Lübbert

Blood (2024) 144 (Supplement 1): 2864.

https://doi.org/10.1182/blood-2024-203583

Published: 2024

Journal Articles

Decider-2: Prospective Randomized Multicenter Phase III Trial of Decitabine and Venetoclax Administered in Combination with All- Trans Retinoic Acid (ATRA) or Placebo in Patients with Acute Myeloid Leukemia Who Are Ineligible for Induction Chemotherapy

Michael Lübbert, Claudia Schmoor, Olga Grishina, Christoph Rummelt, Johanna Thomas, Michael Heuser, Konstanze Döhner, Hartmut Döhner, Heiko Becker, Ralph Wäsch

Blood (2023) 142 (Supplement 1): 1495.

https://doi.org/10.1182/blood-2023-181871

Published: 2023

Journal Articles

Phase I Study of the LSD1 Inhibitor Tranylcypromine (TCP) in Combination with All- Trans Retinoic Acid (ATRA) and Low-Dose Cytarabine (LDAC) in Elderly, Medically Non-Fit Patients with AML or High-Risk MDS (TRANSATRA trial)

Michael Lübbert, Claudia Schmoor, Tobias Berg, Michael Kruszewski, Marcus Matthias Schittenhelm, Katharina Götze, Caroline Pabst, Andrea Kündgen, Tobias Ma, Anna Frey, Kevin Moschallski, Usama-Ur Rehman, Johannes Jung, Justus Duyster, Manfred Jung, Roland Schüle, Ralph Wäsch, Olga Grishina

Blood (2022) 140 (Supplement 1): 9087–9088.

https://doi.org/10.1182/blood-2022-159471

Published: 2022

Journal Articles

Randomized Phase II Study of All- Trans Retinoic Acid and Valproic Acid Added to Decitabine in Newly Diagnosed Elderly AML Patients (DECIDER trial): Predictive Impact of TP53 Status

Blood (2021) 138 (Supplement 1): 2380.

https://doi.org/10.1182/blood-2021-146468

Published: 2021

Journal Articles

Activity of Decitabine (DAC) Combined with All-Trans Retinoic Acid (ATRA) in Oligoblastic AML: Subgroup Analysis of a Randomized 2x2 Phase II Trial

Blood (2020) 136 (Supplement 1): 9–10.

https://doi.org/10.1182/blood-2020-140664

Published: 2020

Journal Articles

Thiotepa-Fludarabine-Treosulfan (TFT) Conditioning for 2nd Allogeneic Peripheral Blood Hematopoietic Cell Transplantation (HCT) from a Second Unrelated Donor in Patients with Acute Myeloid Leukemia (AML) Relapsed after Prior Allogeneic HCT: A Prospective Multicenter Phase II Trial

Jürgen Finke, MD, Claudia Schmoor, Matthias Stelljes, MD, Andreas Burchert, MD, Peter Dreger, Eva-Maria Wagner, MD, Martin Bornhäuser, Kristina Sohlbach, MD, Natalie Schub, MD, Christian Reicherts, Guido Kobbe, Bertram Glass, Hartmut Bertz, MD, Olga Grishina

Blood (2018) 132 (Supplement 1): 210.

https://doi.org/10.1182/blood-2018-99-118999

Published: 2018

Journal Articles

Validation of a Frailty Score Predicting Survival of Elderly, Non-Fit AML Patients Receiving Hypomethylating Therapy: Results of the Decider Trial

Blood (2018) 132 (Supplement 1): 720.

https://doi.org/10.1182/blood-2018-99-115974

Published: 2018

Journal Articles

Impact of Distinct Genetic and Epigenetic Aberrations on Survival and Response in Acute Myeloid Leukemia Patients Receiving Epigenetic Therapy

Jan K. Hiller, MD, Claudia Schmoor, Verena I. Gaidzik, MD, Charlotte Schmidt-Salzmann, MD, Arzu Yalcin, PhD, Mahmoud Abdelkarim, Nadja Blagitko-Dorfs, PhD, Konstanze Döhner, MD, Lars Bullinger, MD, Justus Duyster, MD, Michael Lübbert, MD, Björn Hackanson

Blood (2016) 128 (22): 2839.

https://doi.org/10.1182/blood.V128.22.2839.2839

Published: 2016

Journal Articles

Results of the Randomized Phase II Study Decider (AMLSG 14-09) Comparing Decitabine (DAC) with or without Valproic Acid (VPA) and with or without All- Trans Retinoic Acid (ATRA) Add-on in Newly Diagnosed Elderly Non-Fit AML Patients

Blood (2016) 128 (22): 589.

https://doi.org/10.1182/blood.V128.22.589.589

Published: 2016

Journal Articles

Randomized Trial on GvHD Prophylaxis with or without Anti-Human T-Lymphocyte Immunoglobulin ATG-Fresenius (ATG-F) in Allogeneic Hematopoietic Cell Transplantation from Matched Unrelated Donors: Final Long-Term Results after 8.6 Years Median Follow-up

Jürgen Finke, MD, Claudia Schmoor, PhD, Wolfgang A Bethge, MD, Hellmut Ottinger, Priv.-Doz. Dr. MD, Matthias Stelljes, Liisa Volin, MD PhD, Dominik Heim, MD, Hartmut Bertz, MD, Olga Grishina, MD, Gerard Socie

Blood (2015) 126 (23): 853.

https://doi.org/10.1182/blood.V126.23.853.853

Published: 2015

Journal Articles

Long-Term Follow-up of Therapy-Related MDS and AML Patients Treated with Allogeneic Hematopoietic Cell Transplantation Reveals Substantial 10 Year Survival and Comparably Low Treatment-Related Mortality

Björn Hackanson, MD, Claudia Schmoor, PhD, Hartmut Bertz, Reinhard Marks, Ralph Wäsch, MD, Robert Zeiser, Jürgen Finke, MD

Blood (2014) 124 (21): 1264.

https://doi.org/10.1182/blood.V124.21.1264.1264

Published: 2014

Journal Articles

Randomized Trial On GvHD Prophylaxis with or without Anti T Cell Globulin ATG Fresenius (ATG-F) in Allogeneic Hematopoietic Cell Transplantation From Matched Unrelated Donors: Updated Results and Evaluation of the European Group for Blood and Marrow Transplantation (EBMT) Risk Score.

Juergen Finke, Claudia Schmoor, PhD, Wolfgang A. Bethge, MD, Hellmut Ottinger, MD, Matthias Stelljes, MD, Axel R. Zander, MD, Liisa Volin, Dominik Heim, MD, Rainer Schwerdtfeger, Hartmut Bertz, Olga Grishina, MD, Gerard Socie

Blood (2012) 120 (21): 3090.

https://doi.org/10.1182/blood.V120.21.3090.3090

Published: 2012

Journal Articles

Outcome of Older AML Patients with Adverse Cytogenetics, Including Single or Multiple Monosomies, Treated with the DNA Hypomethylating Agent Decitabine

Michael Lübbert, Claudia Schmoor, Anne Hagemeijer, Björn Hackanson, Rainer Claus, Björn Rüter, Mathias Schmid, Ulrich Germing, MD, Andrea Kuendgen, Volker Rethwisch, Arnold Ganser, MD, Uwe Platzbecker, MD, Oliver Galm, Wolfram Brugger, Gerhard Heil, Pierre W. Wijermans, Konstanze Döhner, Hartmut Döhner

Blood (2011) 118 (21): 2609.

https://doi.org/10.1182/blood.V118.21.2609.2609

Published: 2011

Journal Articles

Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti–T-cell globulin ATG-Fresenius

Blood (2011) 117 (23): 6375–6382.

https://doi.org/10.1182/blood-2011-01-329821

Published: 2011

Includes: Supplemental data

Journal Articles

Chronic Graft-Versus-Host Disease: Lessons From a Randomized Trial on GvHD Prophylaxis with or without Anti-T-Cell Globulin ATG-Fresenius (ATG-F) In Allogeneic Hematopoietic Cell Transplantation (HSCT) From Matched Unrelated Donors

Gérard Socié, Claudia Schmoor, Wolfgang Andreas Bethge, Hellmut Ottinger, Matthias Stelljes, Axel R. Zander, MD, Liisa Volin, Dominik Heim, MD, Rainer Schwerdtfeger, MD, Hartmut Bertz, Olga Grishina, Jurgen Finke, MD

Blood (2010) 116 (21): 212.

https://doi.org/10.1182/blood.V116.21.212.212

Published: 2010

Journal Articles

Is Longer MDS Duration Prior to Non-Intensive AML Treatment a Favorable Prognostic Factor? Results of the 00331 Multicenter Phase II Decitabine Trial

Michael Lubbert, Claudia Schmoor, Björn Rüter, Mathias Schmid, Ulrich Germing, Andrea Kuendgen, Volker Rethwisch, Arnold Ganser, Uwe Platzbecker, Oliver Galm, Wolfram Brugger, Gerhard Heil, Rainer Claus, Barbara Deschler, Björn W. Hackanson, Konstanze Döhner, Pierre Wijermans, Hartmut Döhner

Blood (2010) 116 (21): 2185.

https://doi.org/10.1182/blood.V116.21.2185.2185

Published: 2010

Journal Articles

Randomized Trial on GvHD Prophylaxis with or without Anti-T-Cell Globulin ATG-Fresenius (ATG-F) In Allogeneic Hematopoietic Cell Transplantation From Matched Unrelated Donors: Final Results and Analysis of Prognostic Factors

Jurgen Finke, MD, Claudia Schmoor, Wolfgang Andreas Bethge, Hellmut Ottinger, Matthias Stelljes, Axel R. Zander, MD, Liisa Volin, Dominik Heim, MD, Rainer Schwerdtfeger, MD, Hartmut Bertz, Olga Grishina, Gérard Socié

Blood (2010) 116 (21): 1249.

https://doi.org/10.1182/blood.V116.21.1249.1249

Published: 2010

Journal Articles

Low-Dose Decitabine (DAC), Alone or in Combination with All-Trans Retinoic Acid (ATRA), Is An Active First-Line Treatment in Older AML Patients of All Cytogenetic Risk Groups: Final Results of the FR00331 Multicenter Phase II Study.

Michael Lübbert, Björn H. Rüter, Mathias Schmid, Rainer Claus, Ulrich Germing, Volker Rethwisch, Arnold Ganser, Uwe Platzbecker, Oliver Galm, Wolfram Brugger, Gerhard Heil, Björn Hackanson, Barbara Deschler, Pierre W Wijermans, Claudia Schmoor, Hartmut Döhner

Blood (2009) 114 (22): 4141.

https://doi.org/10.1182/blood.V114.22.4141.4141

Published: 2009

Journal Articles

A Randomized Prospective Multicenter Phase III Trial Comparing Standard GvHD Prophylaxis with Cyclosporine and Methotrexate with Additional Pretransplant ATG Fresenius (ATG-F) in Allogeneic Stem Cell Transplantation from Matched Unrelated Donors

Blood (2008) 112 (11): 57.

https://doi.org/10.1182/blood.V112.11.57.57

Published: 2008

Journal Articles

Continued Treatment with An Outpatient Maintenance Schedule of Decitabine in Older AML Patients Ineligible for Induction Chemotherapy: Results of the 00331 Phase II Multicenter Trial

Michael Lübbert, Mathias Schmid, Björn Rüter, Ulrich Germing, Volker Rethwisch, Arnold Ganser, Uwe Platzbecker, Oliver Galm, Wolfram Brugger, Pierre W Wijermans, Claudia Schmoor, Hartmut Döhner

Blood (2008) 112 (11): 2965.

https://doi.org/10.1182/blood.V112.11.2965.2965

Published: 2008

NARROW

A Prospective, Multicenter Study Assessing Functional and Psychosocial Parameters in AML Patients ≥ 60 Years Receiving Induction Chemotherapy

Decider-2: Prospective Randomized Multicenter Phase III Trial of Decitabine and Venetoclax Administered in Combination with All- Trans Retinoic Acid (ATRA) or Placebo in Patients with Acute Myeloid Leukemia Who Are Ineligible for Induction Chemotherapy

Phase I Study of the LSD1 Inhibitor Tranylcypromine (TCP) in Combination with All- Trans Retinoic Acid (ATRA) and Low-Dose Cytarabine (LDAC) in Elderly, Medically Non-Fit Patients with AML or High-Risk MDS (TRANSATRA trial)

Randomized Phase II Study of All- Trans Retinoic Acid and Valproic Acid Added to Decitabine in Newly Diagnosed Elderly AML Patients (DECIDER trial): Predictive Impact of TP53 Status

Activity of Decitabine (DAC) Combined with All-Trans Retinoic Acid (ATRA) in Oligoblastic AML: Subgroup Analysis of a Randomized 2x2 Phase II Trial

Thiotepa-Fludarabine-Treosulfan (TFT) Conditioning for 2nd Allogeneic Peripheral Blood Hematopoietic Cell Transplantation (HCT) from a Second Unrelated Donor in Patients with Acute Myeloid Leukemia (AML) Relapsed after Prior Allogeneic HCT: A Prospective Multicenter Phase II Trial

Validation of a Frailty Score Predicting Survival of Elderly, Non-Fit AML Patients Receiving Hypomethylating Therapy: Results of the Decider Trial

Impact of Distinct Genetic and Epigenetic Aberrations on Survival and Response in Acute Myeloid Leukemia Patients Receiving Epigenetic Therapy

Results of the Randomized Phase II Study Decider (AMLSG 14-09) Comparing Decitabine (DAC) with or without Valproic Acid (VPA) and with or without All- Trans Retinoic Acid (ATRA) Add-on in Newly Diagnosed Elderly Non-Fit AML Patients

Randomized Trial on GvHD Prophylaxis with or without Anti-Human T-Lymphocyte Immunoglobulin ATG-Fresenius (ATG-F) in Allogeneic Hematopoietic Cell Transplantation from Matched Unrelated Donors: Final Long-Term Results after 8.6 Years Median Follow-up

Long-Term Follow-up of Therapy-Related MDS and AML Patients Treated with Allogeneic Hematopoietic Cell Transplantation Reveals Substantial 10 Year Survival and Comparably Low Treatment-Related Mortality

Randomized Trial On GvHD Prophylaxis with or without Anti T Cell Globulin ATG Fresenius (ATG-F) in Allogeneic Hematopoietic Cell Transplantation From Matched Unrelated Donors: Updated Results and Evaluation of the European Group for Blood and Marrow Transplantation (EBMT) Risk Score.

Outcome of Older AML Patients with Adverse Cytogenetics, Including Single or Multiple Monosomies, Treated with the DNA Hypomethylating Agent Decitabine

Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti–T-cell globulin ATG-Fresenius

Chronic Graft-Versus-Host Disease: Lessons From a Randomized Trial on GvHD Prophylaxis with or without Anti-T-Cell Globulin ATG-Fresenius (ATG-F) In Allogeneic Hematopoietic Cell Transplantation (HSCT) From Matched Unrelated Donors

Is Longer MDS Duration Prior to Non-Intensive AML Treatment a Favorable Prognostic Factor? Results of the 00331 Multicenter Phase II Decitabine Trial

Randomized Trial on GvHD Prophylaxis with or without Anti-T-Cell Globulin ATG-Fresenius (ATG-F) In Allogeneic Hematopoietic Cell Transplantation From Matched Unrelated Donors: Final Results and Analysis of Prognostic Factors

Low-Dose Decitabine (DAC), Alone or in Combination with All-Trans Retinoic Acid (ATRA), Is An Active First-Line Treatment in Older AML Patients of All Cytogenetic Risk Groups: Final Results of the FR00331 Multicenter Phase II Study.

A Randomized Prospective Multicenter Phase III Trial Comparing Standard GvHD Prophylaxis with Cyclosporine and Methotrexate with Additional Pretransplant ATG Fresenius (ATG-F) in Allogeneic Stem Cell Transplantation from Matched Unrelated Donors

Continued Treatment with An Outpatient Maintenance Schedule of Decitabine in Older AML Patients Ineligible for Induction Chemotherapy: Results of the 00331 Phase II Multicenter Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only